Investigate / DGX
Understand QUEST DIAGNOSTICS INC
Can Quest keep its physician and hospital relationships competitive as payment models, hospital behavior and testing market fundamentals change?
Snapshot reviewed 2026-10-02. Source published 2026-07-23. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / DGX
Ask better questions. Keep the evidence.
Explore the available sources for QUEST DIAGNOSTICS INC, then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Quest provides diagnostic information and insights derived from laboratory testing. It serves physicians, hospitals, patients and consumers, health plans, government agencies, employers and other healthcare customers.
Latticework interpretation
What could support the case?
If physicians choose labs on test menu, service, quality and access, Quest's reported offering across these factors could support its position with physician customers.
Latticework interpretation
What could break the case?
If hospitals steer more physician testing toward their own laboratories, Quest could face stronger competition on quality, service scope and pricing.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Quest provides diagnostic information and insights derived from laboratory testing. It serves physicians, hospitals, patients and consumers, health plans, government agencies, employers and other healthcare customers.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $3,043m | $2,761m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $459m | $438m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $320m | $282m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $875m | $858m |
Comparison caveat: Operating cash covers the half-year. The prior period included a payroll tax credit, so the cash comparison is not solely a change in operating earnings.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If physicians choose labs on test menu, service, quality and access, Quest's reported offering across these factors could support its position with physician customers.
Supporting filing ↗The strongest caution
If hospitals steer more physician testing toward their own laboratories, Quest could face stronger competition on quality, service scope and pricing.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How are payment models changing lab economics?
Starting evidence: Value-based reimbursement is increasing and testing market fundamentals are changing, which could affect how laboratory services are priced and purchased.
Investigate next: Review the sections on reimbursement, Medicare rate changes and health plan lab networks for stated effects on revenue and margins.
Read the supporting filing ↗How exposed is Quest to hospital competition?
Starting evidence: Hospitals may steer clinicians toward their own laboratories, strengthening competition for outreach testing.
Investigate next: Look for disclosure on hospital outreach volumes, hospital partnership contracts and any loss of hospital business.
Read the supporting filing ↗Does the hospital partnership channel add durable business?
Starting evidence: Quest reports revenue from reference testing, where it performs tests hospitals do not perform in their own laboratories.
Investigate next: Check for disclosure on contract terms, renewal experience and how management measures hospital channel performance.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.